Claims for Patent: 7,777,050
✉ Email this page to a colleague
Summary for Patent: 7,777,050
| Title: | N3 alkylated benzimidazole derivatives as MEK inhibitors |
| Abstract: | Disclosed are compounds of the Formula I ##STR00001## and pharmaceutically acceptable salts and prodrugs thereof, wherein W, R.sup.1, R.sup.2, R.sup.7, R.sup.8, R.sup.9 and R.sup.10 are as defined in the specification. Such compounds are MEK inhibitors and useful in the treatment of hyperproliferative diseases, such as cancer and inflammation, in mammals. Also disclosed is a method of using such compounds in the treatment of hyperproliferative diseases in mammals, and pharmaceutical compositions containing such compounds. |
| Inventor(s): | Wallace; Eli M. (Lyons, CO), Lyssikatos; Joseph P. (Superior, CO), Marlow; Allison L. (Boulder, CO), Hurley; T. Brian (Boulder, CO) |
| Assignee: | Array BioPharma Inc. (Boulder, CO) |
| Application Number: | 12/050,827 |
| Patent Claims: |
1. A compound selected from 6-(4-bromo-2-fluorophenylamino)-7-fluoro-3-methyl-3H-benzoimidazole-5-car- boxylic acid (2-hydroxyethoxy)-amide and pharmaceutically acceptable
salts thereof.
2. A compound selected from 6-(4-bromo-2-chlorophenylamino)-7-fluoro-3-methyl-3H-benzoimidazole-5-car- boxylic acid (2,3-dihydroxypropoxy)-amide and pharmaceutically acceptable salts thereof. 3. A compound selected from 6-(4-bromo-2-chloro-phenylamino)-7-fluoro-3-methyl-3H-benzoimidazole-5-ca- rboxylic acid (2-hydroxy-1,1-dimethylethoxy)-amide and pharmaceutically acceptable salts thereof. 4. A composition comprising a compound of claim 1 and a pharmaceutically acceptable carrier. 5. A compound selected from: 6-(2,4-Dichloro-phenylamino)-7-fluoro-3-methyl-3H-benzoimidazole-5-carbox- ylic acid (2-hydroxy-ethoxy)-amide and pharmaceutically acceptable salts thereof. 6. A benzoimidazole compound selected from: ##STR00232## and pharmaceutically acceptable salts thereof. 7. A composition comprising a compound of claim 2 and a pharmaceutically acceptable carrier. 8. A composition comprising a compound of claim 3 and a pharmaceutically acceptable carrier. 9. A composition comprising a compound of claim 5 and a pharmaceutically acceptable carrier. |
